-
公开(公告)号：US06919318B1
公开(公告)日：2005-07-19
申请号：US09673798
申请日：1999-04-22
申请人： Xavier Paliard
发明人： Xavier Paliard
IPC分类号： A61K38/00 , A61K38/19 , A61K38/43 , A61K39/21 , A61K39/29 , A61K48/00 , C07K14/00 , C12N15/74
CPC分类号： A61K39/21 , A61K38/195 , A61K39/12 , A61K39/29 , A61K2039/53 , A61K2039/545 , A61K2039/55522 , C12N2740/16234 , C12N2770/24234
摘要： The immune response to a DNA immunogen in a mammal can be enhanced by administration of a chemokine or a polynucleotide encoding the chemokine. This method can be used, for example, to immunize or vaccinate a mammal against an infectious disease or a tumor.
-
公开(公告)号：US06562346B1
公开(公告)日：2003-05-13
申请号：US09698874
申请日：2000-10-27
申请人： Xavier Paliard , Michael Houghton , Mark Selby
发明人： Xavier Paliard , Michael Houghton , Mark Selby
IPC分类号： A61K3929
CPC分类号： C07K14/005 , A61K48/00 , A61K2039/53 , C07K2319/00 , C12N2770/24222
摘要： The invention provides a method of activating hepatitis C virus (HCV)-specific T cells, including CD4+ and CD8+ T cells. HCV-specific T cells are activated using fusion proteins comprising HCV NS3, NS4, NS5a, and NS5b polypeptides, polynucleotides encoding such fusion proteins, or polypeptide or polynucleotide compositions containing the individual components of these fusions. The method can be used in model systems to develop HCV-specific immunogenic compositions, as well as to immunize a mammal against HCV.
-
3.发明申请公开(公告)号：US20050281779A1
公开(公告)日：2005-12-22
申请号：US11095129
申请日：2005-03-29
申请人： Xavier Paliard
发明人： Xavier Paliard
IPC分类号： A61K38/00 , A61K38/19 , A61K38/43 , A61K39/21 , A61K39/29 , A61K48/00 , C07K14/00 , C12N15/74
CPC分类号： A61K39/21 , A61K38/195 , A61K39/12 , A61K39/29 , A61K2039/53 , A61K2039/545 , A61K2039/55522 , C12N2740/16234 , C12N2770/24234
摘要： The immune response to a DNA immunogen in a mammal can be enhanced by administration of a chemokine or a polynucleotide encoding the chemokine. This method can be used, for example, to immunize or vaccinate a mammal against an infectious disease or a tumor.
摘要翻译： 可通过施用趋化因子或编码趋化因子的多核苷酸来增强对哺乳动物中DNA免疫原的免疫应答。 该方法可以用于例如针对传染病或肿瘤免疫或接种哺乳动物。
-
公开(公告)号：US5776708A
公开(公告)日：1998-07-07
申请号：US170114
申请日：1993-12-20
IPC分类号： G01N33/53 , C12Q1/68 , G01N33/50 , G01N33/564 , G01N33/569
CPC分类号： G01N33/564 , C12Q1/6881 , C12Q1/6883 , G01N33/5094 , G01N33/56972 , C12Q2600/158 , G01N2800/102 , G01N2800/24
摘要： The invention relates to a method for identifying T cell populations involved in autoimmune diseases. This involves determining levels of a V.beta. element in a body fluid sample of a patient and comparing this to normal levels. Variation from normal levels is indicative of an autoimmune disease. The invention also involves assaying T cell subpopulations in a sample to determine clonality of .beta. chains. Clonality can also be used to diagnose autoimmune disorders.
摘要翻译： 本发明涉及鉴定参与自身免疫性疾病的T细胞群的方法。 这涉及确定患者体液样本中的Vβ元素的水平，并将其与正常水平进行比较。 与正常水平的变化表明是自身免疫性疾病。 本发明还涉及测定样品中的T细胞亚群以测定β链的克隆性。 克隆性也可用于诊断自身免疫性疾病。
-
公开(公告)号：US20090130762A1
公开(公告)日：2009-05-21
申请号：US11974958
申请日：2007-10-17
申请人： Xavier Paliard , Michael Houghton , Mark Selby
发明人： Xavier Paliard , Michael Houghton , Mark Selby
CPC分类号： C07K14/005 , A61K48/00 , A61K2039/53 , C07K2319/00 , C12N2770/24222
摘要： The invention provides a method of activating hepatitis C virus (HCV)-specific T cells, including CD4+ and CD8+ T cells. HCV-specific T cells are activated using fusion proteins comprising HCV NS3, NS4, NS5a, and NS5b polypeptides, polynucleotides encoding such fusion proteins, or polypeptide or polynucleotide compositions containing the individual components of these fusions. The method can be used in model systems to develop HCV-specific immunogenic compositions, as well as to immunize a mammal against HCV.
摘要翻译： 本发明提供一种激活丙型肝炎病毒（HCV）特异性T细胞，包括CD4 +和CD8 + T细胞的方法。 使用包含HCV NS3，NS4，NS5a和NS5b多肽的融合蛋白，编码这种融合蛋白的多核苷酸或含有这些融合物的各个组分的多肽或多核苷酸组合物来激活HCV特异性T细胞。 该方法可以在模型系统中用于开发HCV特异性免疫原性组合物，以及免疫哺乳动物抗HCV。
-
公开(公告)号：US20090098153A1
公开(公告)日：2009-04-16
申请号：US12231351
申请日：2008-09-02
申请人： Michael Houghton , Steve Coates , Mark Selby , Xavier Paliard
发明人： Michael Houghton , Steve Coates , Mark Selby , Xavier Paliard
IPC分类号： A61K39/00
CPC分类号： C07K14/005 , A61K48/00 , A61K2039/53 , C07K2319/00 , C12N2770/24222
摘要： The invention provides a method of activating hepatitis C virus (HCV)-specific T cells, including CD4+ and CD8+ T cells. HCV-specific T cells are activated using fusion proteins comprising HCV NS3, NS4, NS5a, and NS5b polypeptides, polynucleotides encoding such fusion proteins, or polypeptide or polynucleotide compositions containing the individual components of these fusions. The method can be used in model systems to develop HCV-specific immunogenic compositions, as well as to immunize a mammal against HCV.
-
公开(公告)号：US07638679B2
公开(公告)日：2009-12-29
申请号：US09894845
申请日：2001-06-27
申请人： Xavier Paliard
发明人： Xavier Paliard
IPC分类号： C12N15/00
CPC分类号： C12N15/8509 , A01K2217/05 , A01K2227/105 , A01K2227/106 , A01K2267/0337 , A01K2267/0393 , A61K39/12 , A61K39/29 , A61K2039/505 , A61K2039/545 , A61K2039/57 , C07K14/005 , C12N2750/14143 , C12N2770/24222 , C12N2770/24234 , C12N2830/008 , Y02A50/412
摘要： This invention provides a model for the induction of immunological tolerance to antigens. The tolerance model of the invention can be used for screening candidate drugs effective in modulating tolerance. The invention also provides the use of such tolerance-modulating drugs as agents for the treatment of chronic illnesses, including chronic viral infections, such as HCV.
-
公开(公告)号：US07285539B2
公开(公告)日：2007-10-23
申请号：US10357619
申请日：2003-02-03
申请人： Xavier Paliard , Michael Houghton , Mark Selby
发明人： Xavier Paliard , Michael Houghton , Mark Selby
CPC分类号： C07K14/005 , A61K48/00 , A61K2039/53 , C07K2319/00 , C12N2770/24222
摘要： The invention provides a method of activating hepatitis C virus (HCV)-specific T cells, including CD4+ and CD8+ T cells. HCV-specific T cells are activated using fusion proteins comprising HCV NS3, NS4, NS5a, and NS5b polypeptides, polynucleotides encoding such fusion proteins, or polypeptide or polynucleotide compositions containing the individual components of these fusions. The method can be used in model systems to develop HCV-specific immunogenic compositions, as well as to immunize a mammal against HCV.
摘要翻译： 本发明提供一种激活丙型肝炎病毒（HCV）特异性T细胞，包括CD4 +和CD8 + T细胞的方法。 使用包含HCV NS3，NS4，NS5a和NS5b多肽的融合蛋白，编码这种融合蛋白的多核苷酸或含有这些融合物的各个组分的多肽或多核苷酸组合物来激活HCV特异性T细胞。 该方法可以在模型系统中用于开发HCV特异性免疫原性组合物，以及免疫哺乳动物抗HCV。
-
9.发明授权
公开(公告)号：US5298396A
公开(公告)日：1994-03-29
申请号：US732114
申请日：1991-07-18
IPC分类号： G01N33/53 , C12Q1/68 , G01N33/50 , G01N33/564 , G01N33/569
CPC分类号： G01N33/564 , C12Q1/6881 , C12Q1/6883 , G01N33/5094 , G01N33/56972 , C12Q2600/158 , G01N2800/102 , G01N2800/24
摘要： The invention relates to a method for identifying T cell populations involved in autoimmune diseases. This involves determining levels of a V.beta. element in a body fluid sample of a patient and comparing this to normal levels. Variation from normal levels is indicative of an autoimmune disease. The invention also involves assaying T cell subpopulations in a sample to determine clonality of .beta. chains. Clonality can also be used to diagnose autoimmune disorders.
摘要翻译： 本发明涉及鉴定参与自身免疫性疾病的T细胞群的方法。 这涉及确定患者的体液样品中V（β）元素的水平，并将其与正常水平进行比较。 与正常水平的变化表明是自身免疫性疾病。 本发明还涉及测定样品中的T细胞亚群以确定（β）链的克隆性。 克隆性也可用于诊断自身免疫性疾病。
-
-
-
-
-
-
-
-
搜索结果
9 条记录 (耗时 0.014 秒)
